PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): A network meta-analysis

The combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1+TP) and fluoropyrimidine/ cisplatinum (PD-1+FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with previously untreated, advanced esophageal squamous cell carcinoma (ESCC).